EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lipid nanoparticles-based RNA therapies for breast cancer treatment

Luigia Serpico, Yuewen Zhu, Renata Faria Maia, Sumedha Sumedha, Mohammad-Ali Shahbazi, Hélder A Santos iD

Drug Delivery and Translational Research · 2024-10 · 14 (10) · 2823-2844

DOI: 10.1007/s13346-024-01638-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 03.06.2024. Verfasst von Luigia Serpico und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (…. Hauptthemen laut MEDLINE: Breast Neoplasms, Nanoparticles, Lipids. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE European Innovation Council, HORIZON EUROPE Marie Sklodowska-Curie Actions, Universitair Medisch Centrum Groningen Research Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) prevails as a major burden on global healthcare, being the most prevalent form of cancer among women. BC is a complex and heterogeneous disease, and current therapies, such as chemotherapy and radiotherapy, frequently fall short in providing effective solutions. These treatments fail to mitigate the risk of cancer recurrence and cause severe side effects that, in turn, compromise therapeutic responses in patients. Over the last decade, several strategies have been proposed to overcome these limitations. Among them, RNA-based technologies have demonstrated their potential across various clinical applications, notably in cancer therapy. However, RNA therapies are still limited by a series of critical issues like off-target effect and poor stability in circulation. Thus, novel approaches have been investigated to improve the targeting and bioavailability of RNA-based formulations to achieve an appropriate therapeutic outcome. Lipid nanoparticles (LNPs) have been largely proven to be an advantageous carrier for nucleic acids and RNA. This perspective explores the most recent advances on RNA-based technology with an emphasis on LNPs’ utilization as effective nanocarriers in BC therapy and most recent progresses in their clinical applications. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNanoparticlesLipidsHumansFemaleAnimalsRNAAntineoplastic AgentsLiposomes

Stichwörter der Autor:innen

Breast cancerClinical applicationsGene therapyLipid nanoparticlesRNA technologies

Substanzen

LipidsRNALipid NanoparticlesAntineoplastic AgentsLiposomes

Autor:innen und Institutionen

  • Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands. l.serpico@…
  • Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.
  • Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands. m.a.shahba…
  • Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands. h.a.santos…
  • Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. h.a.santos@umcg.nl.

ORCID-Profile: Hélder A Santos

Förderung

  • HORIZON EUROPE European Innovation Council
  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • Universitair Medisch Centrum Groningen Research Funds

Zitieren

APA

Serpico, L., Zhu, Y., Maia, R. F., Sumedha, S., Shahbazi, M. A., & Santos, H. A. (2024). Lipid nanoparticles-based RNA therapies for breast cancer treatment. Drug Delivery and Translational Research, 14(10), 2823-2844. https://doi.org/10.1007/s13346-024-01638-2

Vancouver

Serpico L, Zhu Y, Maia RF, Sumedha S, Shahbazi MA, Santos HA. Lipid nanoparticles-based RNA therapies for breast cancer treatment. Drug Delivery and Translational Research. 2024;14(10):2823-2844. doi:10.1007/s13346-024-01638-2

BibTeX
@article{Serpico2024,
  author = {Serpico, Luigia and Zhu, Yuewen and Maia, Renata Faria and Sumedha, Sumedha and Shahbazi, Mohammad-Ali and Santos, Hélder A},
  title = {Lipid nanoparticles-based RNA therapies for breast cancer treatment},
  journal = {Drug Delivery and Translational Research},
  year = {2024},
  volume = {14},
  number = {10},
  pages = {2823--2844},
  doi = {10.1007/s13346-024-01638-2}
}
Kostenlos starten →